Sangamo Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: Yahoo! Finance
FDA confirmation that the 52-week mean annualized eGFR slope could support accelerated approval; non-clinical and clinical modules are submitted while the CMC module and first commercial lot completion remain critical and timing is contingent on additional funding. Sangamo has raised over $130 million since early 2025 via licenses, milestone payments and equity, but management says the company's long-term runway is unresolved and securing a commercial partner for Fabry is its top priority while cash is being carefully managed. The company is pivoting toward neurology with ST-503 receiving FDA Fast Track designation for small fiber neuropathy and six active sites, ST-506 CTA-enabling work ongoing, and continued momentum from neurotropic capsid licensing deals (including with Eli Lilly) to drive collaborations. Interested in Sangamo Therapeutics, Inc.? Here are five stocks we like better. 2 low-priced gene therapy stocks to speculate on Sangamo Therapeutics (NASDAQ:SGMO) execu
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- ???????????2035????702.2???????????????(CAGR)22.78%??? [CNET News]CNET News
- Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial ResultsGlobeNewswire
- Here are the major earnings after the close Monday [Seeking Alpha]Seeking Alpha
SGMO
Earnings
- 3/30/26 - Miss
SGMO
Analyst Actions
- 2/10/26 - HC Wainwright
SGMO
Sec Filings
- 3/30/26 - Form 10-K
- 3/30/26 - Form 8-K
- 2/26/26 - Form 4
- SGMO's page on the SEC website